tbResList Print — BITC Benzyl isothiocyanate

Filters: qv=530, qv2=%, rfv=%

Product

BITC Benzyl isothiocyanate
Description: <p><b>Benzyl isothiocyanate</b> Benzyl isothiocyanate (BITC) is a naturally occurring aromatic isothiocyanate and electrophilic organosulfur phytochemical generated from the glucosinolate glucotropaeolin by myrosinase-mediated hydrolysis. <b>Isothiocyanates (pid 476)</b> is its parent chemical class. Natural dietary sources include nasturtium, garden cress, papaya and other plants containing benzyl glucosinolate. BITC has substantial mechanistic and animal anticancer evidence distinct from other isothiocyanates, particularly involving mitochondrial ROS generation, apoptosis, cell-cycle arrest and suppression of STAT3-dependent tumor signaling. It is not an approved anticancer drug and currently lacks convincing human cancer efficacy data.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Mitochondrial respiratory-chain disruption, particularly complex III inhibition, causing ↑ mitochondrial ROS and oxidative stress in susceptible cancer cells.</li>
<li>Intrinsic apoptosis through mitochondrial membrane-potential loss, Bax/Bak activation, XIAP suppression and caspase activation.</li>
<li>G2/M cell-cycle arrest through modulation of cyclin B1, CDK1, CDC25C and related mitotic regulators.</li>
<li>STAT3 suppression with downstream ↓ HIF-1α, VEGF, MMPs and angiogenic/invasive signaling.</li>
<li>Metabolic suppression, including inhibition of CNOT2/c-Myc/STAT3-dependent glycolytic signaling in hepatocellular carcinoma models.</li>
<li>Migration, invasion and metastatic signaling ↓ through context-dependent modulation of EMT, Wnt/β-catenin, Rho-GTPases and related pathways.</li>
<li>Autophagy modulation; BITC can induce ROS-dependent autophagy, although autophagy can be cytotoxic or cytoprotective depending on tumor model.</li>
<li>Secondary NRF2 activation as an adaptive electrophilic/oxidative-stress response; this can increase cytoprotective signaling and is not uniformly anticancer.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> BITC is orally absorbed and extensively metabolized through glutathione conjugation and the mercapturic-acid pathway. Human studies demonstrate urinary excretion of BITC-derived mercapturic-acid metabolites, with one oral study recovering approximately 54% of administered BITC as the major urinary metabolite and most excretion occurring within approximately 10–12 hours. After consumption of benzyl-glucosinolate-containing nasturtium, BITC metabolites and protein conjugates have been detected in plasma, urine and breath. Free BITC exposure is limited by rapid metabolism, chemical reactivity and protein conjugation. Pharmacokinetic characterization at proposed therapeutic anticancer doses remains inadequate.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer experiments use BITC concentrations in the low-micromolar range, commonly approximately 2.5–10 µM. Some investigators describe low-micromolar concentrations as potentially plasma-achievable, but robust human pharmacokinetic data demonstrating sustained free BITC at concentrations used in cancer-cell experiments are lacking. Consequently, direct translation of prolonged in-vitro exposure to oral human dosing remains uncertain. Protein binding/conjugation and rapid mercapturic-acid metabolism further reduce freely available BITC.</p>

<p><b>Clinical evidence status:</b> <b>Preclinical.</b> There is extensive cancer-cell evidence and multiple animal studies demonstrating tumor-growth, angiogenesis and metastasis suppression. Human studies establish dietary absorption and metabolism but do not establish anticancer efficacy. No convincing completed clinical trial of BITC itself as a cancer treatment or chemopreventive intervention was identified. BITC should therefore be distinguished from phenethyl isothiocyanate (PEITC), which has entered human cancer-prevention trials.</p>

<p><b>Safety / translation:</b> Dietary exposure and use as a food flavouring are substantially different from pharmacologic anticancer dosing. JECFA concluded that BITC presented no safety concern at current flavouring-use exposure, but concentrated therapeutic exposure has not been adequately established as safe. BITC is highly electrophilic and concentrated material is an eye and respiratory irritant. Experimental genotoxic effects have been reported at concentrations or doses substantially above normal human dietary exposure. These findings support caution against extrapolating food-level safety to high-dose supplementation.</p>


<h3>Benzyl Isothiocyanate Mechanistic Profile</h3>

<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>

<tr>
<td>1</td>
<td>Mitochondrial respiratory chain and ROS</td>
<td>Complex III activity ↓; mitochondrial ROS ↑</td>
<td>ROS response often substantially lower in tested normal epithelial cells</td>
<td>R</td>
<td>Oxidative stress and initiation of apoptosis ↑</td>
<td>One of the best-supported proximal mechanisms. Mitochondrial DNA-deficient breast-cancer cells are markedly resistant to BITC-induced ROS and apoptosis.</td>
</tr>

<tr>
<td>2</td>
<td>Mitochondrial apoptosis</td>
<td>Membrane potential ↓; Bax/Bak ↑; caspase-9 and caspase-3 ↑; XIAP ↓</td>
<td>Apoptosis generally ↓ relative to susceptible cancer cells in comparative models</td>
<td>R/G</td>
<td>Programmed cell death ↑</td>
<td>ROS occurs upstream of much of the apoptotic response. p53 is not universally required.</td>
</tr>

<tr>
<td>3</td>
<td>Cell-cycle control</td>
<td>G2/M arrest ↑; cyclin B1 ↓; CDK1 ↓; CDC25C ↓</td>
<td>Growth arrest generally less pronounced in tested normal epithelial cells</td>
<td>G</td>
<td>Proliferation ↓</td>
<td>Repeatedly observed across breast, pancreatic, lung and other cancer models.</td>
</tr>

<tr>
<td>4</td>
<td>STAT3 signaling</td>
<td>STAT3 activation ↓</td>
<td>Context-dependent</td>
<td>R/G</td>
<td>Survival, proliferation and angiogenic signaling ↓</td>
<td>Important convergence point in pancreatic cancer and more recent metabolic studies.</td>
</tr>

<tr>
<td>5</td>
<td>HIF-1α VEGF angiogenesis axis</td>
<td>HIF-1α ↓; VEGF ↓; VEGFR2 signaling ↓; MMP-2 ↓</td>
<td>Context-dependent</td>
<td>G</td>
<td>Angiogenesis and invasion ↓</td>
<td>Supported by pancreatic cancer cell, ex-vivo and mouse-tumor experiments and linked mechanistically to STAT3 suppression.</td>
</tr>

<tr>
<td>6</td>
<td>Glycolysis and CNOT2 c-Myc STAT3</td>
<td>CNOT2/c-Myc/STAT3 signaling ↓; glycolytic activity ↓</td>
<td>Insufficient comparative data</td>
<td>G</td>
<td>Metabolic stress and apoptosis ↑</td>
<td>Recent hepatocellular-carcinoma evidence identifies suppression of glycolytic signaling as an important component of BITC-induced apoptosis.</td>
</tr>

<tr>
<td>7</td>
<td>JNK p38 MAPK stress signaling</td>
<td>JNK ↑; p38 MAPK ↑ (ROS-dependent)</td>
<td>Activation substantially weaker or absent in some normal epithelial models</td>
<td>R</td>
<td>Bax activation and apoptosis ↑</td>
<td>Functions downstream of BITC-induced mitochondrial oxidative stress in several models.</td>
</tr>

<tr>
<td>8</td>
<td>Migration invasion and EMT</td>
<td>Migration ↓; invasion ↓; vimentin ↓; MMP signaling ↓</td>
<td>Insufficient comparative data</td>
<td>G</td>
<td>Metastatic phenotype ↓</td>
<td>Supported in head-and-neck, pancreatic, breast and glioma models.</td>
</tr>

<tr>
<td>9</td>
<td>Wnt β-catenin signaling</td>
<td>↓ (model-dependent)</td>
<td>Insufficient comparative data</td>
<td>G</td>
<td>Tumor growth and metastasis ↓</td>
<td>Supported particularly by murine mammary carcinoma studies; probably contextual rather than a universal BITC mechanism.</td>
</tr>

<tr>
<td>10</td>
<td>Autophagy</td>
<td>↑ (context-dependent)</td>
<td>Insufficient comparative data</td>
<td>G</td>
<td>Stress adaptation or cell death</td>
<td>ROS can initiate autophagy. In some prostate-cancer models autophagy is protective, because inhibition of autophagy increases BITC-induced apoptosis.</td>
</tr>

<tr>
<td>11</td>
<td>NRF2 oxidative-stress response</td>
<td>NRF2 ↑ (secondary; context-dependent)</td>
<td>NRF2 ↑ expected as electrophilic stress response</td>
<td>R/G</td>
<td>Cytoprotective antioxidant response ↑</td>
<td>BITC can activate NRF2 through canonical and non-canonical mechanisms. This may counterbalance ROS-mediated cytotoxicity rather than represent a primary anticancer mechanism.</td>
</tr>

<tr>
<td>12</td>
<td>Chemosensitization</td>
<td>Cisplatin response ↑ in selected models</td>
<td>Insufficient data</td>
<td>G</td>
<td>Drug-induced apoptosis ↑</td>
<td>Preclinical evidence includes sensitization of head-and-neck squamous carcinoma cells to cisplatin. Clinical confirmation is absent.</td>
</tr>

<tr>
<td>13</td>
<td>Clinical Translation Constraint</td>
<td>Potentially active at low-micromolar experimental exposure</td>
<td>High-dose safety incompletely defined</td>
<td>G</td>
<td>Clinical applicability uncertain</td>
<td>Rapid metabolism, electrophilic protein binding, uncertain therapeutic human PK, formulation limitations and lack of BITC cancer trials currently restrict translation.</td>
</tr>

</tbody>
</table>

<p><b>TSF:</b> P: 0–30 min&nbsp;&nbsp;&nbsp; R: 30 min–3 hr&nbsp;&nbsp;&nbsp; G: &gt;3 hr</p>

Pathway results for Effect on Cancer / Diseased Cells

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   ARE↑, 1,   GPx4↓, 1,   GSH↓, 4,   HO-1↑, 1,   Iron↑, 1,   lipid-P↑, 1,   MDA↑, 1,   NRF2↑, 2,   ROS?, 1,   ROS↑, 12,   ROS↓, 1,   Trx↑, 2,   TrxR↑, 1,   TrxR1↑, 1,   xCT/SLC7A11↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC2↓, 1,   CDC25↓, 4,   compI↓, 1,   compIII↓, 4,   compIV↓, 1,   ETC↓, 1,   mtDam↑, 1,   OCR↓, 1,   OXPHOS↓, 1,   SDH↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

GlucoseCon↓, 1,   Glycolysis↓, 1,   GSK‐3β↑, 1,   HK2↓, 1,   PDK1 / PDPK1↓, 1,   PKM2↓, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

AIF↑, 1,   APAF1↑, 2,   Apoptosis↑, 14,   Apoptosis?, 1,   BAD↑, 1,   BAX↑, 5,   Bcl-2↓, 5,   Bcl-xL↓, 3,   BIM↑, 1,   Casp↑, 1,   cl‑Casp3↑, 5,   Casp3↑, 5,   proCasp3↓, 1,   Casp7↑, 1,   cl‑Casp7↑, 1,   cl‑Casp8↑, 2,   Casp8↑, 1,   cl‑Casp9↑, 3,   Casp9↑, 2,   Cyt‑c↑, 4,   Ferroptosis↑, 1,   IAP1↓, 1,   iNOS↓, 2,   MDM2↑, 1,   p38↓, 1,   survivin↓, 3,   TumCD↑, 2,   XIAP↓, 6,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑Akt↓, 1,   Akt↓, 3,   cMET↓, 1,   p‑CREB↑, 1,   EGFR↓, 1,   p‑ERK↑, 2,   p‑ERK↓, 1,   ERK↓, 1,   GRB2↓, 2,   HER2/EBBR2↓, 1,   JAK2↓, 1,   JNK↑, 2,   p‑JNK↓, 1,   MAPK↑, 1,   MST1R↓, 1,   mTOR↓, 4,   PI3K↓, 2,   PKCδ↓, 2,   PTEN↑, 1,   RAS↓, 2,   STAT3↓, 5,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 1,   cMyc↓, 1,   DNMTs↓, 1,   FOXO1↓, 1,   FOXO3↓, 1,   H3↝, 1,   H4↝, 1,   HDAC↓, 2,   HDAC1↓, 2,   HDAC3↓, 2,   HDAC6↓, 1,   OCT4↓, 1,   SOX2↓, 1,   tumCV↓, 4,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 6,   P53↑, 3,   p‑P53↑, 1,   cl‑PARP↑, 4,   proPARP↓, 1,   PCNA↓, 3,   Telomerase↓, 2,   γH2AX↑, 1,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 3,   CDK2↓, 3,   CDK4↓, 3,   CDK6↓, 1,   cycA1/CCNA1↓, 2,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 2,   Ki-67↓, 6,   P21↑, 2,   P21↓, 1,   p27/CDKN1B↑, 1,   TumCCA↑, 16,   TumCCA↓, 1,   WEE1↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

cFos↓, 1,   CSCs↓, 4,   Ki-67↓, 6,   Nanog↓, 1,   NOTCH↑, 1,   NOTCH2↑, 1,   STAT1↓, 1,   TumCG↓, 10,   TumCP↓, 7,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AP-1↓, 1,   Ca+2↝, 1,   Ca+2↑, 1,   E-cadherin↑, 4,   EMT↓, 3,   FAK↓, 1,   Fibronectin↓, 1,   MMP2↓, 9,   MMP7↓, 1,   MMP9↓, 6,   PAI-1/SERPINE1↑, 1,   Rho↓, 1,   Slug↓, 1,   Snail↓, 2,   TGF-β↓, 1,   TIMP1↓, 2,   TIMP2↑, 1,   TumCI↓, 8,   TumCMig↓, 7,   TumMeta↓, 4,   uPA↓, 3,   uPAR↓, 1,   Vim↓, 3,   Zeb1↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 6,   CD31/PECAM-1↓, 4,   Hif1a↓, 2,   VEGF↓, 5,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 7,   OCLN↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD44↓, 1,   COX2/PTGS2↓, 1,   CXCR4↓, 3,   IL6↓, 2,   Inflam↓, 1,   NF-kB↓, 4,   NF-kB?, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   SXR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   ChemoSen↑, 3,   CYP3A4↓, 1,   Dose↝, 4,   Dose↑, 1,   eff↓, 3,   eff↑, 3,   eff↝, 2,   P450↓, 1,   RadioS↑, 3,   selectivity↑, 9,   selectivity↝, 1,   Synergy↑, 8,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   EGFR↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 2,   LDH↓, 1,   Polyps↓, 1,   Tumccf↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   AntiTum↑, 3,   chemoPv↑, 2,   Risk↓, 4,   TGFβR1↓, 1,   TumNum↓, 3,   TumVol↓, 1,   TumW↓, 1,   Weight∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 2,   Ingr?, 1,  
Total Targets: 204

Pathway results for Effect on Normal Cells

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 2,   GSTs↑, 1,   HO-1↑, 3,   MDA↓, 2,   MPO↓, 2,   NQO1↑, 3,   NRF2↑, 3,   ROS↓, 3,   ROS⇅, 1,   ROS↑, 1,   SOD↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

NADPH↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   Bax:Bcl2↓, 1,   Casp3↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

MAPK↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP70/HSPA5↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑4E-BP1↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↑, 1,   NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GastroP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD40↓, 1,   DEFB1↑, 1,   IL10↓, 1,   Inflam↓, 2,   IP-10/CXCL-10↓, 1,   NF-kB↓, 1,   PGE2↑, 1,   TNF-α↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   BioAv↑, 2,   Dose?, 1,   Dose↝, 1,   eff↑, 5,  

Functional Outcomes(tgid=23) ⓘ

antiAll↑, 1,   chemoP↑, 1,   hepatoP↑, 1,   RenoP↑, 1,   toxicity↝, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↑, 3,   GutMicro∅, 1,  
Total Targets: 46

Research papers

Year Title Authors PMID Link Flag
2022Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt–mTOR and Cyclin–CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell LinesJochen RutzPMC9570347https://pmc.ncbi.nlm.nih.gov/articles/PMC9570347/0
2011Allyl-, butyl- and phenylethyl-isothiocyanate activate Nrf2 in cultured fibroblastsInsa M A Ernst21109004https://pubmed.ncbi.nlm.nih.gov/21109004/0
2026CNOT2 /c-Myc/STAT3 signaling is critically involved in glycolysis mediated apoptosis of benzyl isothiocyanate in hepatocellular carcinomaWonil KohPMC12921019https://pmc.ncbi.nlm.nih.gov/articles/PMC12921019/0
2024A 14-Day Double-Blind, Randomized, Controlled Crossover Intervention Study with Anti-Bacterial Benzyl Isothiocyanate from Nasturtium (Tropaeolum majus) on Human Gut Microbiome and Host DefenseSimon P PfäfflePMC10857499https://pmc.ncbi.nlm.nih.gov/articles/PMC10857499/0
2024Isothiocyanates in medicine: A comprehensive review on phenylethyl-, allyl-, and benzyl-isothiocyanatesCosima C. Hoch—https://www.sciencedirect.com/science/article/pii/S10436618240005130
2024Benzyl isothiocyanate as an alternative to antibiotics? a comparative in vivo study using Pseudomonas aeruginosaJian Yang—https://visualize.jove.com/38753636-benzyl-isothiocyanate-as-an-alternative-to-antibiotics-a-comparative-in-vivo-study-using-pseudomonas-aeruginosa-infection-as-a-model0
2021Benzyl and phenethyl isothiocyanates as promising epigenetic drug compounds by modulating histone acetylation and methylation marks in malignant melanomaMelina Mitsiogianni33963962https://pubmed.ncbi.nlm.nih.gov/33963962/0
2021Anticancer activities of dietary benzyl isothiocyanate: A comprehensive reviewThao Nhu Dinh33989764https://pubmed.ncbi.nlm.nih.gov/33989764/0
2021Benzyl isothiocyanates modulate inflammation, oxidative stress, and apoptosis via Nrf2/HO-1 and NF-κB signaling pathways on indomethacin-induced gastric injury in ratsShymaa A El Badawy34037056https://pubmed.ncbi.nlm.nih.gov/34037056/0
2019Benzyl isothiocyanate suppresses development and metastasis of murine mammary carcinoma by regulating the Wnt/β-catenin pathwayBei XiePMC6625404https://pmc.ncbi.nlm.nih.gov/articles/PMC6625404/0
2019Benzyl isothiocyanate suppresses development and metastasis of murine mammary carcinoma by regulating the Wnt/β‑catenin pathwayBei XiePMC6625404https://pmc.ncbi.nlm.nih.gov/articles/PMC6625404/0
2018Benzyl isothiocyanate (BITC) triggers mitochondria-mediated apoptotic machinery in human cisplatin-resistant oral cancer CAR cellsChiu-Fang LeePMC6108226https://pmc.ncbi.nlm.nih.gov/articles/PMC6108226/0
2017Benzyl Isothiocyanate potentiates p53 signaling and antitumor effects against breast cancer through activation of p53-LKB1 and p73-LKB1 axesBei XiePMC5223184https://pmc.ncbi.nlm.nih.gov/articles/PMC5223184/0
2017Prevention of breast cancer-induced osteolytic bone resorption by benzyl isothiocyanateSubrata K PorePMC5862255https://pmc.ncbi.nlm.nih.gov/articles/PMC5862255/0
2017Benzyl isothiocyanate induces reactive oxygen species-initiated autophagy and apoptosis in human prostate cancer cellsJi-Fan LinPMC5386757https://pmc.ncbi.nlm.nih.gov/articles/PMC5386757/0
2016Benzyl Isothiocyanate Inhibits Prostate Cancer Development in the Transgenic Adenocarcinoma Mouse Prostate (TRAMP) Model, Which Is Associated with the Induction of Cell Cycle G1 ArrestHan Jin ChoPMC4783993https://pmc.ncbi.nlm.nih.gov/articles/PMC4783993/0
2016Bioavailability and metabolism of benzyl glucosinolate in humans consuming Indian cress (Tropaeolum majus L.)Stefanie Platz26610401https://pubmed.ncbi.nlm.nih.gov/26610401/0
2016Effects of Brassicaceae Isothiocyanates on Prostate CancerSilvia NovíoPMC6272898https://pmc.ncbi.nlm.nih.gov/articles/PMC6272898/0
2015Benzyl isothiocyanate suppresses high-fat diet-stimulated mammary tumor progression via the alteration of tumor microenvironments in obesity-resistant BALB/c miceMinhee Kim24729546https://pubmed.ncbi.nlm.nih.gov/24729546/0
2014Potential mechanisms of benzyl isothiocyanate suppression of invasion and angiogenesis by the U87MG human glioma cell lineYu Zhu25339010https://pubmed.ncbi.nlm.nih.gov/25339010/0
2013Benzyl isothiocyanate induces protective autophagy in human prostate cancer cells via inhibition of mTOR signalingJi-Fan Lin23172666https://pubmed.ncbi.nlm.nih.gov/23172666/0
2013Benzyl isothiocyanate: double trouble for breast cancer cellsChinthalapally V Rao23842793https://pubmed.ncbi.nlm.nih.gov/23842793/0
2013Apoptosis induced by benzyl isothiocyanate in gefitinib-resistant lung cancer cells is associated with Akt/MAPK pathways and generation of reactive oxygen speciesBo-Ning Liu23111983https://pubmed.ncbi.nlm.nih.gov/23111983/0
2012Benzyl isothiocyanate inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate modelHan Jin Cho—https://aacrjournals.org/cancerres/article/72/8_Supplement/609/582931/Abstract-609-Benzyl-isothiocyanate-inhibits0
2011p53-Independent apoptosis by benzyl isothiocyanate in human breast cancer cells is mediated by suppression of XIAP expressionSu-Hyeong KimPMC2881189https://pmc.ncbi.nlm.nih.gov/articles/PMC2881189/0
2011Inhibition of Human Breast Cancer Xenograft Growth by Cruciferous Vegetable Constituent Benzyl IsothiocyanateRenaud WarinPMC2861302https://pmc.ncbi.nlm.nih.gov/articles/PMC2861302/0
2011Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cellsSanjay BatraPMC2946330https://pmc.ncbi.nlm.nih.gov/articles/PMC2946330/0
2011p53 Independent Apoptosis by Benzyl Isothiocyanate in Human Breast Cancer Cells Is Mediated by Suppression of XIAP ExpressionSu-Hyeong KimPMC2881189https://pmc.ncbi.nlm.nih.gov/articles/PMC2881189/0
2011Benzyl isothiocyanate (BITC) inhibits migration and invasion of human gastric cancer AGS cells via suppressing ERK signal pathwaysChin-Chin Ho20498032https://pubmed.ncbi.nlm.nih.gov/20498032/0
2011Benzyl Isothiocyanate Inhibits Epithelial-Mesenchymal Transition in Cultured and Xenografted Human Breast Cancer CellsAnuradha Sehrawat—https://aacrjournals.org/cancerpreventionresearch/article/4/7/1107/49810/Benzyl-Isothiocyanate-Inhibits-Epithelial0
2011Benzyl isothiocyanate sensitizes human pancreatic cancer cells to radiation by inducing apoptosisMaki Ohara21833466https://pubmed.ncbi.nlm.nih.gov/21833466/0
2011Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-α/VEGF/Rho-GTPases: pivotal role of STAT-3Srinivas Reddy BoreddyPMC3189946https://pmc.ncbi.nlm.nih.gov/articles/PMC3189946/0
2011Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c miceEun Ji Kim21170677https://pubmed.ncbi.nlm.nih.gov/21170677/0
2010Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3Su-Hyeong KimPMC3105585https://pmc.ncbi.nlm.nih.gov/articles/PMC3105585/0
2010Benzyl Isothiocyanate–Mediated Inhibition of Histone Deacetylase Leads to NF-κB Turnoff in Human Pancreatic Carcinoma CellsSanjay Batra—https://aacrjournals.org/mct/article/9/6/1596/93819/Benzyl-Isothiocyanate-Mediated-Inhibition-of0
2010Benzyl isothiocyanate inhibits tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in a BALB/c mouse xenograft modelEun Ji Kim—https://aacrjournals.org/cancerres/article/70/8_Supplement/1444/561724/Abstract-1444-Benzyl-isothiocyanate-inhibits-tumor0
2010Benzyl isothiocyanate-mediated growth inhibition of MDA-MB-231 human breast cancer xenograft is associated with reduced cell proliferation, inhibition of angiogenesis, and induction of autophagyAjay Bommareddy—https://aacrjournals.org/cancerres/article/70/8_Supplement/2881/563388/Abstract-2881-Benzyl-isothiocyanate-mediated0
2010Benzyl Isothiocyanate (BITC) Inhibits Migration and Invasion of Human Colon Cancer HT29 Cells by Inhibiting Matrix Metalloproteinase-2/-9 and Urokinase Plasminogen (uPA) through PKC and MAPK Signaling PathwayKuang-Chi Lai—https://pubs.acs.org/jafcau/article-abstract/58/5/2935/208012/Benzyl-Isothiocyanate-BITC-Inhibits-Migration-and?redirectedFrom=fulltext0
2009Benzyl isothiocyanate-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of MAPK in human pancreatic cancer cellsRavi P SahuPMC2757546https://pmc.ncbi.nlm.nih.gov/articles/PMC2757546/0
2008Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cellsDong XiaoPMC2573064https://pmc.ncbi.nlm.nih.gov/articles/PMC2573064/0
2007Inhibitory effects of benzyl isothiocyanate on the proliferation of prostate and breast cancer cellsTeshome Yehualaeshet—https://aacrjournals.org/cancerres/article/67/9_Supplement/5544/538425/Inhibitory-effects-of-benzyl-isothiocyanate-on-the0
2006Benzyl isothiocyanate–induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and BakDong Xiao—https://aacrjournals.org/mct/article/5/11/2931/234875/Benzyl-isothiocyanate-induced-apoptosis-in-human0
2006Benzyl Isothiocyanate-Induced DNA Damage Causes G2/M Cell Cycle Arrest and Apoptosis in Human Pancreatic Cancer CellsRuifen Zhang—https://jn.nutrition.org/article/S0022-3166%2822%2908516-9/fulltext0
2006Effect of Isothiocyanates on Nuclear Accumulation of NF-κB, Nrf2, and Thioredoxin in Caco-2 CellsJana Jakubíková—https://pubs.acs.org/jafcau/article-abstract/54/5/1656/3558744/Effect-of-Isothiocyanates-on-Nuclear-Accumulation?redirectedFrom=fulltext0
2006Benzyl isothiocyanate-induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and BakDong Xiao17121941https://pubmed.ncbi.nlm.nih.gov/17121941/0
2026Isothiocyanates as Ferroptosis Inducers to Promote Cancer Cell DeathValentina CitiPMC13436285https://pmc.ncbi.nlm.nih.gov/articles/PMC13436285/0
2025Molecular Targets of Isothiocyanates in Cancer: Recent AdvancesParul GuptaPMC4122603https://pmc.ncbi.nlm.nih.gov/articles/PMC4122603/0
2025Isothiocyanates inhibit the cisplatin-induced apoptosis and inflammation in human kidney HEK-293 cellsHa-Rin MoonPMC13458007https://pmc.ncbi.nlm.nih.gov/articles/PMC13458007/0
2016CXCR4 is a novel target of cancer chemopreventative isothiocyanates in prostate cancer cellsKozue SakaoPMC4417382https://pmc.ncbi.nlm.nih.gov/articles/PMC4417382/0
2013Erucin and benzyl isothiocyanate suppress growth of late stage primary human ovarian carcinoma cells and telomerase activity in vitroEvelyn Lamy22949403https://pubmed.ncbi.nlm.nih.gov/22949403/0
2012Cancer chemoprevention with dietary isothiocyanates mature for clinical translational researchShivendra V SinghPMC3529556https://pmc.ncbi.nlm.nih.gov/articles/PMC3529556/0